Biotricity Inc. reported a revenue of $4.28 million for the three months ended June 30, 2026, marking a 10.4% increase from $3.87 million in the same period last year. This growth was primarily driven by a 23.6% rise in recurring technology fee revenue, which constituted 97.4% of total revenue. The company's gross profit also improved to $3.53 million, resulting in a gross margin of 82.6%, up from 80.5% in the prior year. However, the company experienced a net loss of $1.07 million, compared to a loss of $0.75 million in the previous year, attributed to a significant increase in selling, general, and administrative expenses, which rose by 26.2% to $2.70 million.
In terms of operational changes, Biotricity has been focusing on expanding its product offerings and market reach. The company launched its Biocore Pro device in October 2023 and has been actively developing its telemedicine platform to enhance remote patient monitoring capabilities. The company has also strengthened its relationships with major tech firms like Amazon and Google, aiming to leverage AI technology for improved healthcare outcomes. As of June 30, 2026, Biotricity's cash reserves stood at $466,503, a significant increase from $149,789 at the end of the previous quarter, reflecting improved cash generation from operations.
The company’s total liabilities increased to $39.72 million as of June 30, 2026, compared to $39.41 million at the end of the previous quarter. This rise was primarily due to an increase in accounts payable and accrued liabilities, which reached $9.30 million. Biotricity's accumulated deficit also widened to $143.64 million, up from $142.57 million in the prior quarter. The company continues to face challenges related to its working capital deficiency, which stood at $31.75 million, raising concerns about its ability to sustain operations without additional funding.
Looking ahead, Biotricity's management remains optimistic about its revenue growth trajectory and plans to enhance liquidity through further business development and capital raising efforts. The company is actively seeking additional equity and debt financing to support ongoing operations and product development. However, management has acknowledged the substantial doubt regarding the company's ability to continue as a going concern, emphasizing the need for timely capital acquisition to avoid potential operational disruptions.
Overall, while Biotricity has made strides in revenue growth and product development, it faces significant financial challenges that necessitate careful management of resources and strategic planning to ensure long-term sustainability and profitability.
About BIOTRICITY INC.
Biotricity Inc. develops FDA-cleared remote biometric monitoring solutions focused on cardiac diagnostics and chronic disease management. Its core products include the Bioflux and Biocore Pro ECG devices and the Bioheart continuous heart monitor, serving physicians, hospitals, and diagnostic testing facilities primarily in the U.S. The company’s insourced, technology-as-a-service model integrates hardware, software, and AI-driven analytics to enhance patient care, improve diagnostic accuracy, and enable cost-effective chronic cardiac care.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov